News and events

The quest to accurately quantify High Mobility Group Box 1 (HMGB1) and its redox variants in human plasma has been a challenging endeavor in biomedical research, due to the complexities presented by interference from other proteins and autoantibodies.

Since its discovery, 50 years ago, the role of HMGB1 protein has shift from mere structural protein in chromatin, to be considered as a key factor in new therapeutic approaches to diseases, such as intracranial aneurysms.

To celebrate the 50th anniversary of the discovery of High Mobility Group Box 1 (HMGB1), it is important to underline its multifaceted roles in cellular biology and disease pathology.

A recent research showed High Mobility Group Box Protein 1 (HMGB1) as a promising biomarker in early sepsis recognition.

Rheumatoid arthritis (RA) is a chronic inflammatory disorder and one of the most common rheumatic diseases; it is characterized by inflammation and pain in the muscles, joints, and fibrous tissue.

On 12th December, Dr Liam Colley, researcher in HMGBiotech, will give an ESR presentation during the Final PhD Conference of RENOIR MSCA-ITN in Lyon, France.

High-mobility group box 1 (HMGB1) is increasingly recognized as a critical player in epilepsy pathogenesis and progression, as demonstrated by studies focusing on its role as a biomarker in the disease.

A study published on Frontiers demonstrated how CXCL12 chemokine plays a pivotal role in various physiological processes, including hematopoiesis, organogenesis, and tissue regeneration.

A recent study has highlighted the role of HMGB1 as a potential mediator in the development of postoperative delirium.